$22.18
0.45% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

IDEAYA Biosciences Inc Stock price

$22.18
+4.73 27.11% 1M
-3.01 11.95% 6M
-3.52 13.70% YTD
-16.75 43.03% 1Y
+13.23 147.82% 5Y
+10.99 98.21% 10Y
+10.99 98.21% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.10 0.45%
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

Key metrics

Market capitalization $1.94b
Enterprise Value $1.25b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 178.58
P/S ratio (TTM) P/S ratio 277.51
P/B ratio (TTM) P/B ratio 1.90
Revenue growth (TTM) Revenue growth -54.84%
Revenue (TTM) Revenue $7.00m
EBIT (operating result TTM) EBIT $-360.35m
Free Cash Flow (TTM) Free Cash Flow $-267.98m
Cash position $692.51m
EPS (TTM) EPS $-3.47
P/E forward negative
P/S forward 140.68
EV/Sales forward 90.53
Short interest 14.14%
Show more

Is IDEAYA Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

IDEAYA Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a IDEAYA Biosciences Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a IDEAYA Biosciences Inc forecast:

Buy
92%
Hold
8%

Financial data from IDEAYA Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7 7
55% 55%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 45 45
48% 48%
637%
- Research and Development Expense 323 323
123% 123%
4,611%
-358 -358
128% 128%
-5,114%
- Depreciation and Amortization 2.37 2.37
5% 5%
34%
EBIT (Operating Income) EBIT -360 -360
126% 126%
-5,148%
Net Profit -307 -307
138% 138%
-4,387%

In millions USD.

Don't miss a Thing! We will send you all news about IDEAYA Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEAYA Biosciences Inc Stock News

Neutral
PRNewsWire
12 days ago
SOUTH SAN FRANCISCO, Calif. , June 2, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.
Neutral
PRNewsWire
15 days ago
SOUTH SAN FRANCISCO, Calif. , May 30, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 29, 2025, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 664,600 shares of the Company...
Neutral
Seeking Alpha
about one month ago
Ideaya Biosciences, Inc. is advancing darovasertib in a phase 2/3 trial for HLA-A2-negative metastatic uveal melanoma patients, with mPFS data expected by end of 2025. Ideaya plans a phase 3 study of darovasertib as a neoadjuvant for uveal melanoma, starting in the first half of 2025. IDE849 is an ADC targeting DLL3 in SCLC and NETs, This program has two catalysts: phase 1 data in Q3 2025 and a...
More IDEAYA Biosciences Inc News

Company Profile

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Yujiro Hata
Employees 131
Founded 2015
Website www.ideayabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today